

**AMENDMENTS TO THE CLAIMS**

This listing of the claims will replace all prior versions, and listings, of claims in this application.

**Listing of Claims:**

1. **(Original)** A method of reducing inflammation in a patient, comprising:  
identifying a patient suffering from or at risk for inflammation; and  
administering to the patient at least one treatment selected from the group consisting of:  
inducing ferritin in the patient; expressing ferritin in the patient; and administering a  
pharmaceutical composition comprising HO-1, bilirubin, biliverdin, ferritin, iron, desferoxamine,  
salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin to the patient, in an amount  
sufficient to reduce inflammation.
2. **(Original)** The method of claim 1, wherein the treatment is inducing ferritin in the  
patient.
3. **(Original)** The method of claim 1, wherein the treatment is expressing ferritin in the  
patient.
4. **(Original)** The method of claim 1, wherein the treatment is administering a  
pharmaceutical composition comprising HO-1 to the patient.
5. **(Original)** The method of claim 1, wherein the treatment is administering a  
pharmaceutical composition comprising biliverdin to the patient.
6. **(Original)** The method of claim 5, wherein the pharmaceutical composition is  
administered to the patient at a dosage of about 1 to 1000 micromoles/kg/day.
7. **(Original)** The method of claim 6, wherein the inflammation is associated with

ulcerative colitis.

8. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising bilirubin to the patient.

9. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising ferritin to the patient.

10. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising desferoxamine (DFO) or salicylaldehyde isonicotinoyl hydrazone (SIH) to the patient.

11. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising iron dextran to the patient.

12. **(Original)** The method of claim 1, wherein the treatment is administering a pharmaceutical composition comprising apoferritin to the patient.

13. **(Original)** The method of claim 2, wherein the ferritin is induced by administering iron to the patient.

14. **(Original)** The method of claim 1, wherein the inflammation is associated with a condition selected from the group consisting of: asthma, adult respiratory distress syndrome, interstitial pulmonary fibrosis, pulmonary emboli, chronic obstructive pulmonary disease, primary pulmonary hypertension, chronic pulmonary emphysema, congestive heart failure, peripheral vascular disease, stroke, atherosclerosis, ischemia-reperfusion injury, heart attacks, glomerulonephritis, conditions involving inflammation of the kidney, infection of the genitourinary tract, viral and toxic hepatitis, cirrhosis, ileus, necrotizing enterocolitis, specific and non-specific inflammatory bowel disease, rheumatoid arthritis, deficient wound healing, Alzheimer's disease, Parkinson's disease, graft versus host disease, and hemorrhagic, septic, or anaphylactic shock.

15. **(Original)** The method of claim 1, wherein the inflammation is inflammation of the heart, lung, liver, spleen, brain, skin, and/or kidney.

16. **(Original)** The method of claim 1, wherein the inflammation is an inflammatory condition localized in the gastrointestinal tract.

17. **(Original)** The method of claim 16, wherein the inflammatory condition is selected from the group consisting of: amoebic dysentery, bacillary dysentery, schistosomiasis, campylobacter enterocolitis, yersinia enterocolitis, enterobius vermicularis, radiation enterocolitis, ischaemic colitis, eosinophilic gastroenteritis, ulcerative colitis, indeterminate colitis, and Crohn's disease.

18. **(Original)** The method of claim 17, wherein the inflammatory condition is ulcerative colitis.

19. **(Original)** The method of claim 1, further comprising the step of administering to the patient at least one treatment selected from the group consisting of: inducing HO-1 in the patient; expressing HO-1 in the patient; and administering a pharmaceutical composition comprising carbon monoxide to the patient.

20. **(Original)** The method of claim 1, further comprising the steps of inducing HOI in the patient, and administering a pharmaceutical composition comprising carbon monoxide to the patient.

21-58. **(Canceled)**

59. **(New)** The method of claim 1, wherein the inflammation is associated with atherosclerosis.

60. **(New)** The method of claim 1, wherein the inflammation is associated with a surgical procedure.

61. (New) The method of claim 60, wherein the surgical procedure is the transplantation of an organ from a donor to the patient.

62. (New) The method of claim 60, wherein the surgical procedure is vascular surgery.